Trial Profile

A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buparlisib (Primary) ; Capmatinib (Primary)
Indications Glioblastoma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Novartis

Most Recent Events

01 Feb 2017 This trial was discontinued in Netherlands as per European Clinical Trials Database record.
12 Jan 2017 Trial has been completed in Spain (end date: 2016-12-23), according to the European Clinical Trials Database record.
01 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com